Mike M. Goldberg

Directeur Général chez Macrophage Therapeutics, Inc.

Profil

Dr. Mike M.
Goldberg, MD MBA, is Chairman at Urigen Pharmaceuticals, Inc., Independent Director at Echo Therapeutics, Inc., and Managing Partner at Montaur Capital Partners LLC.
He is on the Board of Directors at Echo Therapeutics, Inc., Navidea Biopharmaceuticals, Inc., CorNova, Inc., and Angiolight, Inc. Dr. Goldberg was previously employed as Independent Director by Alliqua, Inc., Independent Director by Mast Therapeutics, Inc., Chairman & Chief Executive Officer by Emisphere Technologies, Inc., and VP & Founding Member-Healthcare Banking Group by First Boston Corp.
He also served on the board at HepaLife Technologies, Inc. He received his undergraduate degree from Rensselaer Polytechnic Institute, an MBA from Columbia Business School, and a doctorate degree from Albany Medical College.

Postes actifs de Mike M. Goldberg

Sociétés	Poste	Début
Montaur Capital Partners LLC	Directeur en chef des Investissements	03/11/2010
Vaneltix Pharma, Inc.	Président	01/02/2015
LifeSci Advisors LLC	Corporate Officer/Principal	-
Macrophage Therapeutics, Inc.	Directeur Général	-

Anciens postes connus de Mike M. Goldberg

Sociétés	Poste	Fin
NAVIDEA BIOPHARMACEUTICALS, INC.	Directeur Général	14/08/2018
ECHO THERAPEUTICS, INC.	Président	21/03/2017
Alliqua BioMedical, Inc.	Directeur/Membre du Conseil	15/05/2012
HepaLife Technologies, Inc.	Directeur/Membre du Conseil	06/01/2011
Vaneltix Pharma, Inc.	Directeur/Membre du Conseil	31/08/2010